The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonyms:||anti-CD52 monoclonal antibody |
Monoclonal Antibody Campath-1H
Monoclonal Antibody CD52
|US brand name:||Campath|
|Foreign brand name:||MabCampath|